ASCO 2022

What’s On-Board

ASCO mainly aims at conquering cancer and hopes to create a world where cancer is either prevented or cured with many researches, education, and promotion of the highest quality, and equitable patient care. ASCO proffers a wide range of educational resources in the field of oncology. These resources include several scientific meetings, professional workshops, educational conferences, and special symposia on issues of particular relevance and importance to clinical oncologists and researchers. ASCO is considered to be a major publisher for numerous journals, newsletters, books, and online and multimedia resources.

The ASCO Annual Meeting is considered to be the largest premier international forum for the presentation of scientific research and state-of-the-art education in the field of clinical oncology. The five-day mega-event will attract more than 30,000 attendees across the world. Various outcomes and findings from clinical trials are presented at the ASCO's Annual Meeting which represents mainly the significant progress made each year in the fight against cancer. Thousands of scientific abstracts will be released at the ASCO Annual Meeting, with the latest updates and findings from cancer clinical trials, which also include new drug studies, and can possibly change the perspective of cancer patient care.

Schedule A One-To-One Meeting with Our Delegates At ASCO 2022. Meet us on June 3-7, 2022, simply by filling up the form towards the right.

Oncology Portfolio Management

DelveInsight’s Oncology Portfolio Management services provides exceptionally unmatched assistance in understanding competencies in the oncology market. In addition to that, we prioritize strategic goals, assess the changes in oncology industry, understand the current needs of the cancer market and likewise work on creating value for client services.

Rare Cancer Analysis

DelveInsight aims at providing effective reports that tally with the rare cancer market. Our analysts track developmental, regulatory & commercial milestones of competitor products. It includes aspects such as conference assessment, and company and R&D development assessment to carry out the desired development of oncological product for commercial purposes dealing with client’s area of interest.

Consulting Services

Our multidimensional, purposeful, and credible consultancy services will help in accelerating oncology product services, it includes aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, diagnostic landscape assessment to overcome several challenges in the oncology market.

Competitive Intelligence

We have a specialized primary Competitive Intelligence research team that has expertise in the field of oncology. It constitutes analysts, senior analysts, and managers. Our CI force provides the best possible opportunities and most accurate intelligence that can be accumulated and provide to our partners. In addition, exceptionally well and a collection of cancer data with a fundamental goal of acquiring best-in-class intelligence and providing oncology analysis with respect to different cancer therapeutics to achieve the consultation goal of our partners.

R&D Analysis

Our research and development analyst understands the oncology realm to create value based decisions and help clients achieve better oncological R&D endeavors. Any oncological drug's journey through pre-clinical and clinical development is done by assessing the same parameters of other candidates already in the space. Similar is done for the oncology drugs as well. DelveInsight’s insight-packed oncological reports provide clarity on uncertainties and challenge blind spots to provide timely intelligence to the company.

Pipeline Assessment

DelveInsight’s Oncological Pipeline Assessment promises an overarching view of cancer therapies, their clinical trials, as well as each and every highlight of cancer therapeutics landscape in a report format. Encompassing oncology ready reports already present in our Report Store, our Pipeline Assessment report type provides insights across therapies, MoAs, Drugs, APIs, as well as Launch Insights of drugs in late stage of development to provide understanding of their launch timelines and strategies.

We welcome you to discuss your business-related concerns and we can together find the best possible solution to help you proceed further in the Biotechnology and Pharma market.

    Sadaf Javed

    Ms. Sadaf Javed is currently working in the Forecasting team with experience of almost 6 years in hand and expertise in creating indication-based pharma forecasting dynamic models. They include important categories such as disease epidemiology analysis, current market sales analysis, and upcoming market sizing estimations. An exceptionally skilled consultant, she is also involved in client interaction and has worked in several therapeutic areas including Neurological disorders, rare indications, autoimmune disorders, and Oncology. In addition to that, her responsibility extends by covering many International Oncology Conferences such as ASCO, and ESMO.

    Rajesh Kumar

    Rajesh is an extremely enthusiastic and dedicated professional who is self motivated, hard working and having decision making ability. With more than 10+ years of experience in market research having expertise in Market intelligence, BD&L, Strategic Planning and Forecasting. Throughout these years his major focus was Oncology and Rare Diseases space.

The ASCO 2022 conference and exhibition will take place from 3rd to 7th of June, 2022 with an in-person meeting attendance in the skyline and skyscraper city of Chicago, Illinois.

Save the Date!
June 3-7, 2022

Get in Touch with Us